Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034
- Author
- VAN DEN BENT, Martin J; BRANDES, Alba A; ARMAND, Jean-Paul; TAPHOORN, Martin J. B; TOSONI, Alicia; KLETZL, Heidemarie; KLUGHAMMER, Barbara; LACOMBE, Denis; GORLIA, Thierry; RAMPLING, Roy; KOUWENHOVEN, Mathilde C. M; KROS, Johan M; CARPENTIER, Antoine F; CLEMENT, Paul M; FRENAY, Marc; CAMPONE, Mario; BAURAIN, Jean-Francois
[1] Daniel den Hoed Cancer Center, Rotterdam, Netherlands
[2] Medisch Centrum Haaglanden, the Hague, Netherlands
[3] Medical Oncology Department, Bellaria-Maggiore Hospital, Bologna, Italy
[4] Beatson Oncology Centre, Glasgow, United Kingdom
[5] Hopital de la Salpêtrière, Paris, France
[6] Centre Antoine Lacassagne, Nice, France
[7] Centre Rene Gauducheau, Nantes, St. Herblain, France
[8] Institute Gustave Roussy, Villejuif, France
[9] Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
[10] Cliniques Universitaires St, Luc, Brussels, Belgium
[11] European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
[12] F. Hoffmann-La Roche Ltd, Basel, Switzerland - Source
Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1268-1274, 7 p ; ref : 23 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancérologie Carmustine Erlotinib Essai clinique phase II Essai clinique Etude comparative Glioblastome Randomisation Récidive Tumeur intracrânienne Témozolomide EORTC Agent alkylant Cancer Dérivé de la quinazoline Enzyme Gliome malin Inhibiteur de la tyrosine kinase Inhibiteur enzyme Moutarde à l'azote Nitrosourées Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Cancerology Carmustine Erlotinib Phase II trial Clinical trial Comparative study Glioblastoma Randomization Relapse Intracranial tumor Temozolomide European Organization for Research and Treatment of Cancer Alkylating agent Cancer Quinazoline derivatives Enzyme Malignant glioma Tyrosine kinase inhibitor Enzyme inhibitor Nitrogen mustard Nitrosoureas Cerebral disorder Central nervous system disease Nervous system diseases Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cancerología Carmustina Erlotinib Ensayo clínico fase II Ensayo clínico Estudio comparativo Glioblastoma Aleatorización Recaida Tumor intracraneal Temozolomida Agente alquilante Cáncer Enzima Glioma maligno Inhibidor tyrosine kinase Inhibidor enzima Mostaza al nitrógeno Nitrosoureas Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17E Tumors of the nervous system. Phacomatoses
- Discipline
- Neurology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 21252116
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2008.17.5984 
https://dx.doi.org/10.1200/JCO.2008.17.5984
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1268\";s:8:\"\u0000*\u0000epage\";s:4:\"1274\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"VAN DEN BENT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Martin J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"BRANDES, Alba A\";i:1;s:17:\"ARMAND, Jean-Paul\";i:2;s:21:\"TAPHOORN, Martin J. B\";i:3;s:14:\"TOSONI, Alicia\";i:4;s:18:\"KLETZL, Heidemarie\";i:5;s:19:\"KLUGHAMMER, Barbara\";i:6;s:14:\"LACOMBE, Denis\";i:7;s:15:\"GORLIA, Thierry\";i:8;s:13:\"RAMPLING, Roy\";i:9;s:26:\"KOUWENHOVEN, Mathilde C. M\";i:10;s:13:\"KROS, Johan M\";i:11;s:21:\"CARPENTIER, Antoine F\";i:12;s:15:\"CLEMENT, Paul M\";i:13;s:12:\"FRENAY, Marc\";i:14;s:14:\"CAMPONE, Mario\";i:15;s:22:\"BAURAIN, Jean-Francois\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1268\";s:8:\"\u0000*\u0000epage\";s:4:\"1274\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"VAN DEN BENT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Martin J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"BRANDES, Alba A\";i:1;s:17:\"ARMAND, Jean-Paul\";i:2;s:21:\"TAPHOORN, Martin J. B\";i:3;s:14:\"TOSONI, Alicia\";i:4;s:18:\"KLETZL, Heidemarie\";i:5;s:19:\"KLUGHAMMER, Barbara\";i:6;s:14:\"LACOMBE, Denis\";i:7;s:15:\"GORLIA, Thierry\";i:8;s:13:\"RAMPLING, Roy\";i:9;s:26:\"KOUWENHOVEN, Mathilde C. M\";i:10;s:13:\"KROS, Johan M\";i:11;s:21:\"CARPENTIER, Antoine F\";i:12;s:15:\"CLEMENT, Paul M\";i:13;s:12:\"FRENAY, Marc\";i:14;s:14:\"CAMPONE, Mario\";i:15;s:22:\"BAURAIN, Jean-Francois\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1268\";s:8:\"\u0000*\u0000epage\";s:4:\"1274\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"VAN DEN BENT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Martin J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"BRANDES, Alba A\";i:1;s:17:\"ARMAND, Jean-Paul\";i:2;s:21:\"TAPHOORN, Martin J. B\";i:3;s:14:\"TOSONI, Alicia\";i:4;s:18:\"KLETZL, Heidemarie\";i:5;s:19:\"KLUGHAMMER, Barbara\";i:6;s:14:\"LACOMBE, Denis\";i:7;s:15:\"GORLIA, Thierry\";i:8;s:13:\"RAMPLING, Roy\";i:9;s:26:\"KOUWENHOVEN, Mathilde C. M\";i:10;s:13:\"KROS, Johan M\";i:11;s:21:\"CARPENTIER, Antoine F\";i:12;s:15:\"CLEMENT, Paul M\";i:13;s:12:\"FRENAY, Marc\";i:14;s:14:\"CAMPONE, Mario\";i:15;s:22:\"BAURAIN, Jean-Francois\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1268\";s:8:\"\u0000*\u0000epage\";s:4:\"1274\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"VAN DEN BENT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Martin J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"BRANDES, Alba A\";i:1;s:17:\"ARMAND, Jean-Paul\";i:2;s:21:\"TAPHOORN, Martin J. B\";i:3;s:14:\"TOSONI, Alicia\";i:4;s:18:\"KLETZL, Heidemarie\";i:5;s:19:\"KLUGHAMMER, Barbara\";i:6;s:14:\"LACOMBE, Denis\";i:7;s:15:\"GORLIA, Thierry\";i:8;s:13:\"RAMPLING, Roy\";i:9;s:26:\"KOUWENHOVEN, Mathilde C. M\";i:10;s:13:\"KROS, Johan M\";i:11;s:21:\"CARPENTIER, Antoine F\";i:12;s:15:\"CLEMENT, Paul M\";i:13;s:12:\"FRENAY, Marc\";i:14;s:14:\"CAMPONE, Mario\";i:15;s:22:\"BAURAIN, Jean-Francois\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.5984\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1268\";s:8:\"\u0000*\u0000epage\";s:4:\"1274\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"VAN DEN BENT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Martin J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"BRANDES, Alba A\";i:1;s:17:\"ARMAND, Jean-Paul\";i:2;s:21:\"TAPHOORN, Martin J. B\";i:3;s:14:\"TOSONI, Alicia\";i:4;s:18:\"KLETZL, Heidemarie\";i:5;s:19:\"KLUGHAMMER, Barbara\";i:6;s:14:\"LACOMBE, Denis\";i:7;s:15:\"GORLIA, Thierry\";i:8;s:13:\"RAMPLING, Roy\";i:9;s:26:\"KOUWENHOVEN, Mathilde C. M\";i:10;s:13:\"KROS, Johan M\";i:11;s:21:\"CARPENTIER, Antoine F\";i:12;s:15:\"CLEMENT, Paul M\";i:13;s:12:\"FRENAY, Marc\";i:14;s:14:\"CAMPONE, Mario\";i:15;s:22:\"BAURAIN, Jean-Francois\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma : EORTC Brain Tumor Group Study 26034\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
